Diagnosing atherosclerosis makes Nuclear Medicine a tissue imaging modality.

Area of Science:

• Nuclear medicine and molecular imaging.
• Cardiovascular disease research.
• Radiopharmaceutical development.

Background:

• Atherosclerosis, a key contributor to cardiovascular events and mortality, involves inflammation and calcification.
• Current imaging methods like (18)F-FDG PET/CT and CT angiography identify atherosclerosis but may miss early molecular changes.
• Arterial calcification, assessed by CT and PET, is a known risk factor, but its early molecular detection remains a challenge.

Discussion:

• (18)F-NaF PET/CT offers a novel approach to detect early molecular calcification in atherosclerotic plaques.
• This technique assesses global molecular cardiovascular calcification before macroscopic changes are visible or detectable by CT.
• The uptake of (18)F-NaF in the heart and aorta increases with age, suggesting its potential as a biomarker.

Key Insights:

• (18)F-NaF PET/CT is the first non-invasive imaging method capable of identifying and localizing high-risk coronary plaques.
• This method provides insights into active molecular calcification preceding clinically significant cardiovascular events.
• Findings suggest a potential shift in understanding cardiovascular risk assessment through early molecular detection.

Outlook:

• Further research is needed to establish the definitive role of (18)F-NaF PET/CT in predicting cardiovascular events.
• This nuclear medicine technique represents a significant advancement in the diagnosis and study of cardiovascular diseases.
• Potential for integration into routine screening protocols for high-risk individuals.